Emotional and Mental Health Resources: Teens and Young Adults

Besides the normal turmoil of adolescence, receiving a diagnosis of Juvenile Myositis can present your child with more stress due to changes in body image, medical visits, medications, etc.

It is important to recognize the warning signs of depression and anxiety. Adjusting to life with Juvenile Myositis is difficult, but we are here to help.


Dr. Polly Livermore
Paediatric Rheumatology Senior Nurse Academic from Great Ormond Street Hospital, London

“From my recent UK study asking children and young people to talk about their experience with JM, we showed how important it is for health care professionals to actually ask the children and teens themselves how they are coping. JM patients told us that they often feel different from their peers and siblings and suffer from feelings of uncertainty as the illness, medication side effects, and future pathways into adulthood can be unpredictable. Thanks, Cure JM, for helping to support these children, young people, and families all over the world!”

Executive Director Update - A Season of Gratitude

Season of Gratitude

I am writing to wish you and your family the very best this Holiday Season. This time of year, especially, I am filled with deep appreciation for all that Cure JM families have accomplished to advance our mission, to improve the lives of children living with JM, and to support the doctors and researchers driving better treatments as we fight for a cure.

Affordable and Accessible Treatments for JM

Affordable and Accessible Treatments for JM

Two special guest speakers, Michelle Vogel, MPA, IV Solutions RX, and Laurel Cherwin, BSN, RN, IgCN, Octapharma, shared information on navigating affordable treatments and care for JM patients.

The FDA’s Ruling on Vamorolone in DMD

You may have heard about yesterday’s FDA ruling, which approved vamorolone as an alternative steroid for use in Duchenne muscular dystrophy.

Vamorolone is a new steroid alternative with fewer side effects than prednisone. The drug aims to preserve the beneficial anti-inflammatory and muscle-strengthening characteristics of corticosteroids, while decreasing some of the unwelcome side effects, including bone fragility, delayed growth, and behavior changes.

As we learned in yesterday’s announcement, vamorolone was found to be both safe and effective as a therapy for Duchenne muscular dystrophy in its newly approved indication.

Join Cure JM

Membership is free and we’ll connect you with a network of support, encouragement, and resources.

Cure JM supports families, patients, and the juvenile myositis research community.

Interested in DIY fundraising but need help?

We’re here to help!

To have your fundraiser matched, add “DIY Match” in the memo of your online gift or check.